Abstract In the setting of benign prostatic obstruction related to hyperplasia, novel treatment strategies based on new mini-invasive techniques are currently in development. UroLift implants are the most developed and…
Abstract The introduction of laser energy for the treatments of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) has dramatically changed the surgical landscape of surgery for…
Abstract Several drugs have been approved for the treatment of nonneurogenic lower urinary tract symptoms (LUTS). 5α-Reductase inhibitors (5ARIs) and α1-blockers (AB) represent the mainstay of medical treatment of male…
Abstract Currently, transurethral prostatectomy (TURP) is considered one of the best surgical treatments for benign prostatic hyperplasia. Prostate volume is an important factor in choosing a suitable modality. Although studies…
Abstract Storage type lower urinary tract symptoms (LUTS) are the most bothersome for patients. Several pharmacotherapies directed at the treatment of storage LUTS have emerged over the last decade, including…
Abstract Lower urinary tract symptoms (LUTS) are very common in both sexes, especially in aged population and negatively affect health-related quality of life of afflicted individuals. The prevalence of benign…
Abstract Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting the elderly male. Current management options for BPH and for lower urinary tract symptoms (LUTS) related…
Abstract Diagnostic work-up of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia aims to detect/quantify the three disease components (LUTS, benign prostatic enlargement, and benign prostatic obstruction (BPO)), estimate disease progression,…
Abstract With age, men experience an increase in the volume of prostrate stroma (histologically diagnosed as benign prostatic hyperplasia (BPH); static component), and an increase in the alpha-1 adrenergic receptors…
Abstract Alpha-blockers are the mainstay of lower urinary tract symptoms (LUTS) in relation with benign prostatic obstruction (BPO). Their use is extensively recommended in men with LUTS as a firstline…
